IPILIMUMAB（MDX-010）で臨床試験のデータベースNIH ClinicalTrials.govを検索した結果です（2019年11月3日検索）

1. Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery (Phase 1) NCT00025181
2. Novel Adjuvants for Peptide-Based Melanoma Vaccines (Phase 1) NCT00028431
3. Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma (Phase 2) NCT00032045
4. Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer (Phase 1) NCT00039091
5. Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy (Phase 1) NCT00047164
6. Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma (Phase 2) NCT00050102
7. Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer (Phase 2) NCT00050596
8. Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer (Phase 2) NCT00057889
9. Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT00058279
10. Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (Phase 1) NCT00060372
11. Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer (Phase 1) NCT00064129
12. CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer (Phase 1|Phase 2) NCT00075192
13. Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma (Phase 2) NCT00077532
14. Study of MDX-010 in Stage IV Breast Cancer (Phase 2) NCT00083278
15. Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma (Phase 2) NCT00084656
16. CP-675,206 In Patients With Advanced Melanoma (Phase 2) NCT00086489
17. MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma (Phase 1|Phase 2) NCT00089076
18. CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery (Phase 1) NCT00090896
19. MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma (Phase 3) NCT00094653
20. MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery (Phase 2) NCT00112580
21. Vaccine and Antibody Treatment of Prostate Cancer (Phase 1) NCT00113984
22. A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide (Phase 2) NCT00135408
23. A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma (Phase 2) NCT00140855
24. A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies (Phase 2) NCT00162123
25. Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer (Phase 2) NCT00170157
26. Study of CP-675,206 in Refractory Melanoma (Phase 2) NCT00254579
27. CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy (Phase 3) NCT00257205
28. Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010) (Phase 1|Phase 2) NCT00261365
29. A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT00289627
30. Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT00289640
31. Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT00312975
32. Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer (Phase 1|Phase 2) NCT00323882
33. Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma (Phase 3) NCT00324155
34. Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma (Phase 2) NCT00357461
35. Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection (Phase 1) NCT00362713
36. Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma (Phase 1) NCT00372853
37. A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued. (Phase 2) NCT00378482
38. Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody (Phase 1) NCT00431275
39. Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma (Phase 2) NCT00471887
40. Safety And Efficacy Study Of CP-675,206 In HIV-Infected Patients (Phase 2) NCT00488995
41. Compassionate Use Trial for Unresectable Melanoma With Ipilimumab () NCT00495066
42. Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) (Phase 2) NCT00527735
43. A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer (Phase 1) NCT00556023
44. Treatment Use Study for Advanced Melanoma. () NCT00584493
45. A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma (Phase 1) NCT00585000
46. CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin’s Lymphoma, ALL & CLL (Phase 1) NCT00586391
47. Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases (Phase 2) NCT00623766
48. Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma (Phase 3) NCT00636168
49. Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma (Not Applicable) NCT00685750
50. CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer (Phase 1) NCT00702923
51. Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (Phase 1) NCT00729950
52. Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia (Phase 1) NCT00732186
53. Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma (Phase 1) NCT00790010
54. Drug-Drug Interaction – 3 Arm – Carboplatin/Paclitaxel, Dacarbazine (Phase 1) NCT00796991
55. Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma (Phase 1) NCT00803374
56. Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer (Phase 1) NCT00836407
57. Study of Immunotherapy to Treat Advanced Prostate Cancer (Phase 3) NCT00861614
58. Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT00871481
59. Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer (Phase 1) NCT00880854
60. Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma (Phase 1) NCT00920907
61. Long-term Data Collection for Subjects in MDX-010 Studies () NCT00928031
62. Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma (Early Phase 1) NCT00972933
63. Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma (Phase 2) NCT01008358
64. Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma (Phase 1) NCT01024231
65. Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma (Phase 2) NCT01034787
66. Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer (Phase 3) NCT01057810
67. Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma (Phase 1) NCT01103635
68. Ipilimumab + Temozolomide in Metastatic Melanoma (Phase 2) NCT01119508
69. Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01134614
70. Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer (Phase 1) NCT01165216
71. Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma (Phase 1) NCT01176474
72. Neoadjuvant Ipilimumab in Prostate Cancer (Phase 2) NCT01194271
73. Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1 (Phase 2) NCT01216696
74. Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma (Phase 1) NCT01245556
75. Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer (Phase 1) NCT01255800
76. Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (Phase 3) NCT01274338
77. Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin (Phase 3) NCT01285609
78. Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (Phase 1) NCT01295827
79. Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma (Phase 2) NCT01302496
80. Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity (Phase 2) NCT01323517
81. The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer (Phase 2) NCT01331525
82. Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients (Phase 1) NCT01334099
83. THE IPI – Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease (Phase 2) NCT01355120
84. Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma (Phase 2) NCT01363206
85. Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (Phase 2) NCT01377389
86. Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) (Phase 1) NCT01400451
87. IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma (Phase 1) NCT01409174
88. IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma (Phase 1|Phase 2) NCT01409187
89. Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer (Phase 1) NCT01445379
90. Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy (Phase 2) NCT01449279
91. Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone (Phase 3) NCT01450761
92. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) (Phase 1) NCT01454102
93. Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer (Phase 2) NCT01471197
94. Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) (Phase 1) NCT01472081
95. Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery (Phase 1) NCT01473940
96. A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 (Phase 2) NCT01480323
97. Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma (Phase 1) NCT01489059
98. Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or Without Sargramostim () NCT01489423
99. Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma (Phase 2) NCT01495988
100. Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma (Phase 1) NCT01496807
101. RADVAX邃｢: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMA (Phase 1|Phase 2) NCT01497808
102. Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (Phase 2) NCT01498978
103. Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer (Phase 1) NCT01502592
104. Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer (Phase 1) NCT01510288
105. A Multi-National, Prospective, Observational Study in Patients With Unresectable or Metastatic Melanoma () NCT01511913
106. Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab (Phase 3) NCT01515189
107. First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma (Phase 2) NCT01524991
108. Ipilimumab and GMCSF Immunotherapy for Prostate Cancer (Phase 2) NCT01530984
109. Study of Radiotherapy Administered in Combination With Ipilimumab in Patients With Unresectable Stage III or Stage IV Advanced Malignant Melanoma (Phase 1) NCT01557114
110. Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma (Phase 2) NCT01565837
111. Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (Phase 2) NCT01585194
112. An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy (Phase 2) NCT01585987
113. Doxycycline, Temozolomide and Ipilimumab in Melanoma (Phase 1|Phase 2) NCT01590082
114. An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma (Phase 1|Phase 2) NCT01592370
115. A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Phase 1|Phase 2) NCT01604889
116. Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-ﾎｱ2b for Melanoma (Phase 1) NCT01608594
117. Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer (Phase 2) NCT01611558
118. PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma (Phase 1) NCT01621490
119. Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic (Phase 1) NCT01643278
120. A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma (Phase 2) NCT01654692
121. An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer (Phase 1|Phase 2) NCT01658878
122. A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma (Phase 1) NCT01672450
123. Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma (Phase 2) NCT01673854
124. Ipilimumab With Carboplatin and Paclitaxel in Patients With Unresectable Stage III and Stage IV Melanoma (Phase 2) NCT01676649
125. Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma (Phase 2) NCT01681212
126. Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naﾃｯve Patients With Progressive Metastatic Castration-resistant Prostate Cancer (Phase 1|Phase 2) NCT01688492
127. Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT01689870
128. Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma (Phase 2) NCT01689974
129. Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer (Phase 2) NCT01693783
130. Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma (Phase 2) NCT01696045
131. Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts (Not Applicable) NCT01701674
132. Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma (Phase 1) NCT01703507
133. Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01708941
134. Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma (Phase 2) NCT01709162
135. Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer (Phase 1) NCT01711515
136. A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT01714739
137. Study of Ipilimumab in the Immune System (Not Applicable) NCT01715077
138. Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma (Phase 1) NCT01729806
139. Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases (Early Phase 1) NCT01730157
140. Ipilimumab and Imatinib Mesylate in Advanced Cancer (Phase 1) NCT01738139
141. Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma (Phase 1|Phase 2) NCT01740297
142. CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma (Phase 2) NCT01740401
143. Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma (Phase 1|Phase 2) NCT01743157
144. Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor (Phase 1) NCT01750580
145. Ipilimumab and Lenalidomide in Advanced Cancer (Phase 1) NCT01750983
146. Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia (Phase 1) NCT01757639
147. Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities () NCT01758575
148. Study of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable Melanoma (Phase 1) NCT01767454
149. Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer (Phase 1|Phase 2) NCT01769222
150. Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064) (Phase 2) NCT01783938
151. Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy (Early Phase 1) NCT01789827
152. Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (Phase 2) NCT01804465
153. NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma (Phase 1) NCT01810016
154. Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT01820754
155. Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (Phase 1) NCT01822509
156. Phase II Study of Abraxane Plus Ipilimumab in Patients With Metastatic Melanoma (Phase 2) NCT01827111
157. Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer (Phase 1) NCT01832870
158. Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma (Phase 1) NCT01838200
159. Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma (Phase 2) NCT01840007
160. Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) (Phase 1) NCT01840579
161. Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) (Phase 3) NCT01844505
162. HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma (Phase 4) NCT01856023
163. Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) (Phase 3) NCT01866319
164. A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer (Phase 2) NCT01896869
165. Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (Phase 1|Phase 2) NCT01896999
166. Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma (Phase 2) NCT01913691
167. Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies (Phase 2) NCT01919619
168. Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma (Phase 2) NCT01927419
169. A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors (Phase 1|Phase 2) NCT01928394
170. Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (Phase 1) NCT01935921
171. Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery (Phase 1) NCT01940809
172. SRS (Stereotactic Radiosurgery) Plus Ipilimumab (Phase 1) NCT01950195
173. Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT01950390
174. Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma (Phase 2) NCT01970527
175. Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized “Proof-of-principle” Phase II Study (Phase 2) NCT01973322
176. MSB0010445 and Stereotactic Body Radiation Therapy in Advanced Melanoma (Phase 2) NCT01973608
177. A Two-arm, Single Center Phase 1b Trial of Bavituximab Plus Ipilimumab in Advanced Melanoma Patients (Phase 1) NCT01984255
178. LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab (Phase 1) NCT01986426
179. Clinical Evaluation of Yervoy in Combination With Adoptive T Cell Transfer for Metastatic Melanoma Patients (Phase 2) NCT01988077
180. Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients (Phase 2) NCT01990859
181. A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma (Phase 1) NCT01996202
182. Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer (Phase 1) NCT01998126
183. Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin Diftitox (Phase 2) NCT02009384
184. A Phase I/II Open-Label Study of Ipilimumab and GM-CSF Administered to Unresectable Stage IIIC and Stage IV Melanoma Patients (Phase 1|Phase 2) NCT02009397
185. A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients (Phase 3) NCT02017717
186. Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy (Phase 2) NCT02020070
187. Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4 (Phase 2) NCT02027935
188. Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma (Phase 1) NCT02032810
189. A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) (Phase 1|Phase 2) NCT02039674
190. Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease (Phase 2) NCT02046733
191. Ipilimumab 12-month Intensive Pharmacovigilance Protocol () NCT02050594
192. Immunotherapy Study for Patients With Stage IV Melanoma (Phase 2) NCT02054520
193. An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread (Phase 2) NCT02060188
194. A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. (Phase 4) NCT02068196
195. Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies (Phase 1) NCT02070406
196. Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02073123
197. Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma (Phase 1) NCT02077114
198. Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) () NCT02083484
199. Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) (Phase 1|Phase 2) NCT02089685
200. Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (Phase 2) NCT02094391
201. Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery (Phase 2) NCT02097732
202. Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma (Phase 2) NCT02107755
203. T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer (Early Phase 1) NCT02113657
204. GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases (Phase 2) NCT02115139
205. Trial of Neoadjuvant Ipilimumab Followed by Melphalan Via Isolated Limb Infusion for Patients With Unresectable In-transit Extremity Melanoma (Phase 1) NCT02115243
206. Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma (Phase 1) NCT02117362
207. Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer (Phase 2|Phase 3) NCT02154490
208. Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery (Phase 2) NCT02158520
209. A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors (Phase 1) NCT02174172
210. Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma () NCT02186249
211. Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation (Phase 2) NCT02196961
212. Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma (Phase 1) NCT02200562
213. High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery (Phase 2) NCT02203604
214. Adoptive Therapy Using Antigen-Specific CD4 T-Cells (Phase 1) NCT02210104
215. Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery (Early Phase 1) NCT02210117
216. Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) (Phase 2) NCT02221739
217. YERVOYﾂｮ Risk Minimization Tool Effectiveness Evaluation Survey () NCT02224768
218. Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma (Phase 3) NCT02224781
219. Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) (Phase 3) NCT02231749
220. Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors (Phase 1|Phase 2) NCT02239900
221. A Phase I/II Study of Intratumoral Injection of SD-101 (Phase 1|Phase 2) NCT02254772
222. RTA 408 Capsules in Patients With Melanoma – REVEAL (Phase 1|Phase 2) NCT02259231
223. Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC (Phase 2) NCT02259621
224. A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma (Phase 2) NCT02272855
225. Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma (Phase 1|Phase 2) NCT02275416
226. Study Comparing TIL to Standard Ipilimumab in Patients With Metastatic Melanoma (Phase 3) NCT02278887
227. Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (Phase 3) NCT02279732
228. Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive (Phase 2) NCT02279862
229. Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (Phase 1|Phase 2) NCT02304458
230. Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (Phase 2) NCT02306850
231. Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI) (Phase 1) NCT02307149
232. Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma (Phase 1) NCT02311920
233. Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer (Phase 2) NCT02314169
234. An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself (Phase 2) NCT02320058
235. Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (Phase 2|Phase 3) NCT02339571
236. Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs (Phase 2) NCT02350764
237. Anti窶娠D 1 Brain Collaboration for Patients With Melanoma Brain Metastases (Phase 2) NCT02374242
238. Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer (Phase 1) NCT02381314
239. A Phase I/II Trial to Evaluate a Peptide Vaccine Plus Ipilimumab in Patients With Melanoma (Phase 1|Phase 2) NCT02385669
240. Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238) (Phase 3) NCT02388906
241. Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia (Phase 2) NCT02397720
242. Ipilimumab 60-month Pharmacovigilance Protocol for Advanced Melanoma Patients Who Are Hepatitis B and/or Hepatitis C Virus Positive in Taiwan () NCT02402699
243. Ipilimumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma (Phase 2) NCT02403778
244. Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma (Phase 1) NCT02406183
245. Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (Phase 1) NCT02408861
246. A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma (Phase 1|Phase 2) NCT02413827
247. Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer (Phase 1) NCT02423928
248. Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (Phase 2) NCT02428192
249. Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients (Phase 1) NCT02437279
250. Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy () NCT02449837
251. Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma (Phase 1|Phase 2) NCT02452281
252. Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) (Phase 2) NCT02452294
253. Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer (Phase 1) NCT02453620
254. A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis (Phase 3) NCT02460068
255. A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers (Phase 1|Phase 2) NCT02467361
256. Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer (Phase 1) NCT02475213
257. An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (Phase 3) NCT02477826
258. An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors (Phase 1|Phase 2) NCT02488759
259. PAN-EU Utilization, Effectiveness and Safety of Ipilimumab Administered in EAP Patients With Advanced Melanoma () NCT02492815
260. Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (Phase 1) NCT02496208
261. Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Phase 2) NCT02498600
262. Cytokine-induced Killer Study for Patients With Stage II Melanoma (Phase 2) NCT02498756
263. Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (Phase 2) NCT02500797
264. Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer (Phase 2) NCT02506114
265. High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (Phase 3) NCT02506153
266. A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors (Phase 1) NCT02516527
267. Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery (Phase 2) NCT02519322
268. Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED (Phase 2) NCT02523313
269. Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) (Phase 2) NCT02530463
270. MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer (Phase 2) NCT02536794
271. An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy (Phase 3) NCT02538666
272. A Comparative Study in Chinese Subjects With Chemotherapy Naﾃｯve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine (Phase 3) NCT02545075
273. Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) (Phase 2) NCT02553642
274. Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy () NCT02581228
275. Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma (Phase 3) NCT02599402
276. Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy. () NCT02600143
277. Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7 (Phase 2) NCT02601014
278. A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients (Phase 1) NCT02608437
279. Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases (Phase 2) NCT02621515
280. Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer (Not Applicable) NCT02626130
281. Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma (Phase 2) NCT02626962
282. Sequential Combo Immuno and Target Therapy (SECOMBIT) Study (Phase 2) NCT02631447
283. A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02644967
284. An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma (Phase 2) NCT02648997
285. BrUOG 324: Adjuvant Nivolumab and Low Dose Ipilimumab for Stage III and Resected Stage IV Melanoma: A Phase II Brown University Oncology Research Group Trial (Phase 2) NCT02656706
286. An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT02658890
287. Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (Phase 2) NCT02659059
288. A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma (Phase 1) NCT02659540
289. Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases (Phase 2) NCT02662725
290. Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies (Phase 1) NCT02668770
291. Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas (Phase 1) NCT02675439
292. Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence (Phase 1|Phase 2) NCT02681302
293. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (Phase 2) NCT02693535
294. Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer (Phase 1|Phase 2) NCT02696993
295. RATIO: Rational Approach To Immuno-Oncology (Not Applicable) NCT02700971
296. Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer (Phase 2) NCT02701400
297. Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT02703623
298. A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (Phase 3) NCT02714218
299. Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients (Phase 2) NCT02716272
300. Yervoyﾂｮ Postmarketing Surveillance for Patients in Japan With Unresectable, Malignant Melanoma () NCT02717364
301. Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (Phase 1) NCT02723006
302. Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy (Phase 2) NCT02731729
303. Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone (Phase 1|Phase 2) NCT02736123
304. An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT02737475
305. Study of Autoimmune Disease Complications Following Ipilimumab Treatment Among Melanoma Patients With Underlying Autoimmune Diseases () NCT02739386
306. Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Phase 3) NCT02741570
307. Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma (Phase 2) NCT02743819
308. An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer (Phase 2) NCT02750514
309. Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery (Phase 1) NCT02754856
310. Ipilimumab-induced Lung Toxicity: Observational Study () NCT02755233
311. An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo (Phase 2) NCT02763761
312. Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study () NCT02780089
313. GI Complications in Cancer Immunotherapy Patients () NCT02784366
314. Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Phase 3) NCT02785952
315. Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma (Phase 2) NCT02794883
316. Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery (Phase 1) NCT02812420
317. Ipilimumab for Head and Neck Cancer Patients (Phase 1) NCT02812524
318. Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (Phase 2) NCT02823574
319. Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas (Phase 1) NCT02829931
320. A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer (Not Applicable) NCT02833233
321. Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (Phase 2) NCT02834013
322. Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (Phase 1) NCT02846376
323. Yervoy Pregnancy Surveillance Study () NCT02854488
324. A Trial Evaluating the Safety & Efficacy of Intra-Tumoral Ipilimumab in Combination With Intra-venous Nivolumab in Patients With Metastatic Melanoma (Phase 1|Phase 2) NCT02857569
325. A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy (Phase 3) NCT02864251
326. Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients (Phase 2) NCT02866383
327. An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers (Phase 4) NCT02869789
328. Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer (Phase 3) NCT02872116
329. Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia (Phase 1) NCT02879695
330. Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery (Phase 2) NCT02880020
331. Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer (Phase 2) NCT02888743
332. Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia (Phase 1) NCT02890329
333. Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer (Phase 2) NCT02892734
334. Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients (Phase 3) NCT02899299
335. JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors (Phase 1|Phase 2) NCT02904226
336. A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma (Phase 3) NCT02905266
337. Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases (Phase 1|Phase 2) NCT02913417
338. Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma (Phase 2) NCT02917772
339. Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity (Phase 2) NCT02919683
340. IL2 Imaging in Metastatic Melanoma (Not Applicable) NCT02922283
341. A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma (Phase 1) NCT02922764
342. A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers (Phase 2) NCT02923934
343. A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer (Phase 2) NCT02935634
344. Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab (Phase 1) NCT02935790
345. Definition of an Immune Signature Predictive of Anti-PD1 (Programmed Death-1) Antibody in the Treatment of Advanced Melanoma () NCT02938728
346. Ipilimumab and Nivolumab in Leptomeningeal Metastases (Phase 2) NCT02939300
347. Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced/Metastatic Renal Cell Carcinoma After Prior Therapy () NCT02940639
348. A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases (Phase 1|Phase 2) NCT02941744
349. A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma (Phase 1) NCT02950766
350. Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (Phase 2) NCT02953457
351. A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naﾃｯve Metastatic Kidney Cancer (Phase 2) NCT02960906
352. Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy (Phase 2) NCT02968303
353. Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma (Phase 2) NCT02970981
354. Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (Phase 2) NCT02977052
355. Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (Phase 1) NCT02977156
356. A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab (Phase 2) NCT02978443
357. A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma (Phase 2) NCT02982486
358. A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (Phase 4) NCT02982954
359. A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors (Phase 1|Phase 2) NCT02983045
360. Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT02985957
361. Real-Life Efficacy and Safety of Nivolumab Monotherapy or in Combination With Ipilimumab in Patients With Advanced (Unresectable or Metastatic) Melanoma and in Patients With Adjuvant Nivolumab Therapy () NCT02990611
362. Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours (Phase 2) NCT02992912
363. A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma (Phase 2) NCT02996110
364. A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) (Phase 3) NCT02998528
365. An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (Phase 2) NCT03001882
366. ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (Phase 1|Phase 2) NCT03003637
367. Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver (Phase 1) NCT03005002
368. Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (Phase 1|Phase 2) NCT03009058
369. PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas (Phase 1|Phase 2) NCT03013491
370. Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (Phase 2) NCT03026062
371. Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity (Phase 2) NCT03026140
372. A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer (Phase 1|Phase 2) NCT03026166
373. An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma (Phase 2) NCT03029780
374. Ipilimumab With or Without Nivolumab in Treating Patients With Melanoma That Is Stage IV or Stage III and Cannot Be Removed by Surgery (Phase 2) NCT03033576
375. Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer (Phase 3) NCT03036098
376. Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (Phase 1|Phase 2) NCT03043599
377. A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (Phase 3) NCT03048136
378. Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma (Phase 2) NCT03048474
379. Precise Local Injection of Anti-cancer Drugs Using Presage’s CIVO邃｢ Device in Soft Tissue Sarcoma (Phase 1) NCT03056599
380. Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature (Phase 2) NCT03061539
381. Trial of SBRT in Combination With Nivolumab/Ipilimumab in RCC / Kidney Cancer Patients (Phase 2) NCT03065179
382. An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (Phase 3) NCT03068455
383. Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Participants With Metastatic Uveal Melanoma (Phase 1) NCT03068624
384. Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma (Phase 2) NCT03070392
385. Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma (Phase 2) NCT03071406
386. Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC (Phase 2) NCT03075423
387. BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer (Phase 2) NCT03083691
388. Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer (Phase 2) NCT03091491
389. Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma (Phase 2) NCT03097939
390. Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (Phase 1) NCT03098160
391. Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer (Phase 2) NCT03101566
392. Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer (Phase 2) NCT03104439
393. First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03110107
394. Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma (Phase 2) NCT03117309
395. A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy (Phase 2) NCT03122522
396. Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies (Phase 1|Phase 2) NCT03126110
397. SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients (Phase 2) NCT03126461
398. An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (Phase 2) NCT03130959
399. Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer (Early Phase 1) NCT03132467
400. SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma (Phase 1|Phase 2) NCT03138161
401. A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma (Phase 3) NCT03138512
402. Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases () NCT03140137
403. A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Phase 3) NCT03141177
404. A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (Phase 3) NCT03143153
405. Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer (Phase 1) NCT03144778
406. Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer (Phase 2) NCT03146650
407. Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab (Phase 2) NCT03149159
408. A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma (Phase 2) NCT03153085
409. Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer (Phase 2) NCT03158129
410. Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma (Phase 1|Phase 2) NCT03161756
411. Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer (Early Phase 1) NCT03162731
412. Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread () NCT03165409
413. A Real-World Study of Ipilimumab Treatment After Nivolumab Treatment in Melanoma in Japan () NCT03165422
414. Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632) (Phase 1|Phase 2) NCT03168464
415. Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Phase 2) NCT03171064
416. Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer (Phase 2) NCT03172624
417. Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (Phase 2) NCT03177239
418. Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer (Phase 2) NCT03190265
419. Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (Phase 1|Phase 2) NCT03195478
420. Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver Cancer (Phase 1) NCT03203304
421. Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study) (Phase 2) NCT03203473
422. A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors (Phase 1) NCT03203876
423. Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer (Phase 2) NCT03204812
424. A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (Phase 3) NCT03215706
425. Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS) (Phase 2) NCT03219671
426. Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma (Phase 2) NCT03219775
427. Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma (Phase 2) NCT03220009
428. Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer (Phase 2) NCT03222076
429. Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung Cancer (Phase 1) NCT03223155
430. Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma (Not Applicable) NCT03225365
431. Safety and Pharmacokinetics of REGN2810 (Anti-PD-1) in Japanese Patients With Advanced Malignancies (Phase 1) NCT03233139
432. Intra-tumoral Ipilimumab Plus Intravenous Nivolumab Following the Resection of Recurrent Glioblastoma (Phase 1) NCT03233152
433. Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib (Phase 2) NCT03235245
434. A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies (Phase 1|Phase 2) NCT03241173
435. Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma (Phase 2) NCT03241186
436. Nivolumab Plus Ipilimumab in Thyroid Cancer (Phase 2) NCT03246958
437. A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03251924
438. Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC (Phase 2) NCT03256136
439. Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer. (Phase 2) NCT03262779
440. Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation (Phase 1|Phase 2) NCT03271047
441. Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma (Phase 2) NCT03274258
442. Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma (Phase 1) NCT03283046
443. Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC) (Phase 2) NCT03285321
444. TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer (Phase 1|Phase 2) NCT03287674
445. TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (Phase 1) NCT03293784
446. Adoptive Cell Therapy Across Cancer Diagnoses (Phase 1|Phase 2) NCT03296137
447. Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma (Phase 1|Phase 2) NCT03297463
448. Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (Phase 2) NCT03297593
449. Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (Phase 2) NCT03297606
450. Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598) (Phase 3) NCT03302234
451. Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL (Phase 1|Phase 2) NCT03305445
452. Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery (Phase 2) NCT03307616
453. Expanded Access for Pembrolizumab (MK-3475) () NCT03311542
454. Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma (Phase 2) NCT03313323
455. Study of Adverse Renal Effects of Immune Checkpoints Inhibitors () NCT03316417
456. Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery (Phase 1|Phase 2) NCT03326258
457. Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors (Phase 2) NCT03333616
458. An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (Phase 1) NCT03335540
459. Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) (Phase 2) NCT03340129
460. Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients (Phase 2) NCT03342417
461. A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies (ECHO-208) (Phase 1|Phase 2) NCT03347123
462. TNF in Melanoma Patients Treated With Immunotherapy (Not Applicable) NCT03348891
463. Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab (Phase 2) NCT03350126
464. Randomized Phase III Study Testing Nivolumab and Ipilimumab Versus a Carboplatin Based Doublet in First Line Treatment of PS 2 or Elderly Patients With Advanced Non-small Cell Lung Cancer (Phase 3) NCT03351361
465. ANRS CO24 OncoVIHAC (Onco VIH Anti Checkpoint) () NCT03354936
466. Induction of Immune-mediated aBscOpal Effect thrOugh STEreotactic Radiation Therapy in Metastatic Melanoma Patients Treated by PD-1 + CTLA-4 Inhibitors (BOOSTER MELANOMA) (Phase 1|Phase 2) NCT03354962
467. BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas (Phase 2) NCT03355976
468. Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma (Phase 2) NCT03367715
469. An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT03369223
470. VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer (Phase 1) NCT03373188
471. Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer (Phase 2) NCT03373760
472. Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer (Phase 1|Phase 2) NCT03377023
473. An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread (Phase 1|Phase 2) NCT03377361
474. Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions () NCT03387540
475. Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (Phase 1) NCT03387761
476. Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory Cancers (Phase 1) NCT03388632
477. Phase III Trial of (LCT) After Nivolumab and Ipilimumab (Phase 3) NCT03391869
478. Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma (Phase 2) NCT03396952
479. Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy (Phase 1|Phase 2) NCT03404960
480. Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (Phase 2) NCT03406247
481. Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac – Patients With Small Cell Lung Cancer (SCLC) (Phase 2) NCT03406715
482. A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV) (Phase 1) NCT03407105
483. CAVATAKﾂｮ and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER) (Phase 1) NCT03408587
484. Biomarkers of Immune-Related Toxicity () NCT03409016
485. Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer (Phase 2) NCT03409198
486. Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer (Phase 3) NCT03409614
487. Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma (Phase 2) NCT03409848
488. A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer (Phase 2) NCT03416244
489. Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors (Phase 2) NCT03420521
490. Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma (Phase 1) NCT03422094
491. A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer (Phase 1) NCT03425292
492. Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC (Phase 2) NCT03425331
493. Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma (Phase 1) NCT03425461
494. A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer (Phase 2) NCT03430063
495. Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naﾃｯve, Recurrent Glioblastoma (Phase 2) NCT03430791
496. Combination of Chemoradiation With Immunotherapy in Inoperable ﾅ都ophageal Cancer (Phase 2) NCT03437200
497. Survival Study for Participants Treated With Ipilimumab-Nivolumab Combination Therapy () NCT03438279
498. PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC (Phase 2) NCT03442569
499. Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence (Phase 2) NCT03443856
500. An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (Phase 1) NCT03444753
501. A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) (Phase 3) NCT03445533
502. Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom () NCT03448497
503. Long Term Quality of Life in Melanoma Patients in Netherlands () NCT03450876
504. Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers (Phase 1) NCT03452332
505. Investigation of the Timely-coordinated Therapy of Patients With Metastatic Cancer by Radiotherapy Together With Immune Checkpoint Inhibition () NCT03453892
506. Improved Therapy Response Assessment in Metastatic Brain Tumors () NCT03458455
507. An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (Phase 1|Phase 2) NCT03459222
508. An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas () NCT03460782
509. Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe) (Phase 2) NCT03461952
510. Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma (Early Phase 1) NCT03463408
511. Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (Phase 2) NCT03468985
512. Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr (Phase 3) NCT03469960
513. Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver (Phase 2) NCT03472586
514. Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer (Phase 1) NCT03477864
515. Immune CHeckpoint Inhibitors Monitoring of Adverse Drug ReAction () NCT03492242
516. Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade (Phase 1) NCT03493932
517. Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer (Phase 1) NCT03507699
518. Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis (Phase 1) NCT03508570
519. Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients (Phase 1) NCT03509584
520. Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) (Phase 2) NCT03510871
521. REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer (Phase 3) NCT03515629
522. A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy (Phase 2) NCT03520491
523. Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma (Phase 2) NCT03521830
524. Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (Phase 1|Phase 2) NCT03522584
525. ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid Tumors (Phase 1|Phase 2) NCT03525795
526. A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes (Early Phase 1) NCT03526185
527. Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLC (Phase 1) NCT03527251
528. Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma (Phase 2) NCT03528408
529. Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer (Phase 1) NCT03532217
530. UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma (Phase 1) NCT03538314
531. Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer (Phase 2) NCT03546686
532. Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc) (Phase 2) NCT03548428
533. Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma (Phase 2) NCT03552380
534. Melanoma Metastasized to the Brain and Steroids (Phase 2) NCT03563729
535. A Phase 1b Study of the Selective HDAC Inhibitor Mocetinostat in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 1) NCT03565406
536. Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations (Phase 2) NCT03570619
537. Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLC (Phase 2) NCT03573947
538. A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer (Phase 1|Phase 2) NCT03575793
539. Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer (Phase 1|Phase 2) NCT03581487
540. Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (Phase 2) NCT03591731
541. A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma (Phase 1) NCT03597282
542. PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (Phase 2) NCT03598816
543. Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (Phase 1) NCT03600155
544. Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer (Phase 2) NCT03601455
545. Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma (Phase 1|Phase 2) NCT03604978
546. Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery (Phase 2|Phase 3) NCT03604991
547. Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner (Phase 1|Phase 2) NCT03618134
548. CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease (Phase 2) NCT03618641
549. A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck (Phase 2) NCT03620123
550. Evaluation of Sphingolipids as Predictive Biomarkers of Immune Checkpoint Inhibitor Response in Melanoma Patients (Not Applicable) NCT03627026
551. CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab (Phase 2) NCT03638141
552. A Study of a Personalized Neoantigen Cancer Vaccine (Phase 1|Phase 2) NCT03639714
553. Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma (Phase 2) NCT03646617
554. Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer (Phase 2) NCT03647969
555. Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients (Phase 2) NCT03650894
556. Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer (Phase 2) NCT03651271
557. Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC) (Phase 1|Phase 2) NCT03663166
558. A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread () NCT03663946
559. A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (Phase 2) NCT03668119
560. A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy (Phase 2) NCT03670056
561. Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma (Phase 1|Phase 2) NCT03682276
562. VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck Cancer (Phase 1) NCT03690986
563. INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma (Not Applicable) NCT03692338
564. A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors (Phase 2) NCT03693014
565. Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors (Phase 2) NCT03693846
566. A Data Collection Study for Patients With Adenocarcinoma Treated With the MyVaccx Immunotherapy Regimen. () NCT03695835
567. Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy (Phase 3) NCT03700905
568. Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma (Phase 1) NCT03707457
569. Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab (Phase 1) NCT03707808
570. A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma (Phase 2) NCT03711188
571. Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy (Phase 2) NCT03719131
572. Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression (Phase 2) NCT03724968
573. RACIN in Patients With Advanced TIL-negative Solid Tumors (Phase 1) NCT03728179
574. Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma (Phase 2) NCT03728465
575. A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US () NCT03732560
576. Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers (Phase 1|Phase 2) NCT03749460
577. Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome (Phase 2) NCT03767439
578. VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma (Phase 1) NCT03769155
579. Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer (Phase 1|Phase 2) NCT03776487
580. Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer – a Combination Immunotherapy Phase Ib Study. (Phase 1) NCT03784040
581. NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (Phase 2) NCT03789110
582. Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (Phase 3) NCT03793166
583. Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer (Phase 1) NCT03798639
584. Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma (Phase 2) NCT03799445
585. CAcTUS – Circulating Tumour DNA Guided Switch (Phase 2) NCT03808441
586. Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers (Phase 1) NCT03816332
587. Anetumab Ravtansine With Nivolumab, Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Mesothelin Positive Advanced Pancreatic Cancer (Phase 1) NCT03816358
588. Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease (Phase 2) NCT03818685
589. An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC) (Phase 2) NCT03823625
590. CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer (Phase 1) NCT03829111
591. NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (Phase 2) NCT03832621
592. A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study (Phase 1|Phase 2) NCT03844256
593. Radiation and Combination Immunotherapy for Melanoma (Phase 2) NCT03850691
594. Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) (Phase 2) NCT03865082
595. Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (Phase 2) NCT03866382
596. Autoantibodies in Treatment With Immune Checkpoint Inhibitors (AUTENTIC) () NCT03868046
597. An Immunotherapy Study of Nivolumab Plus Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (Phase 3) NCT03873402
598. Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain (Phase 2) NCT03873818
599. A Personalized Medicine Study for Patients With Advanced Cancer of the Breast, Prostate, Pancreas or Those With Refractory Acute Myelogenous Leukemia (Phase 1) NCT03878524
600. A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer (Phase 2|Phase 3) NCT03879122
601. Optune Device – TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain Metastasis (Phase 2) NCT03903640
602. A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (Phase 1) NCT03912064
603. Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer (Phase 2) NCT03914300
604. Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma (Phase 1|Phase 2) NCT03918252
605. Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma (Phase 1) NCT03922880
606. Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma (Phase 1) NCT03929029
607. Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (Phase 3) NCT03937219
608. Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors (Phase 2) NCT03945773
609. Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis (Phase 1|Phase 2) NCT03949153
610. A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (Phase 1|Phase 2) NCT03953235
611. An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (Phase 1) NCT03956680
612. IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma (Phase 1|Phase 2) NCT03958383
613. Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma (Phase 2) NCT03959293
614. Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial (Phase 3) NCT03977571
615. A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment (Phase 1) NCT03978611
616. Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy (Phase 1) NCT03982121
617. Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer (Phase 2) NCT03989362
618. PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors (Phase 2) NCT03993379
619. A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma (Phase 2) NCT03999749
620. IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With Recurrent or Refractory Glioblastoma (Phase 1) NCT04003649
621. Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma (Phase 2) NCT04006262
622. A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma (Phase 2) NCT04007588
623. A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (Phase 3) NCT04008030
624. Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer (Phase 1) NCT04013542
625. Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab (Phase 2) NCT04013854
626. BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (Phase 1|Phase 2) NCT04021043
627. Safety and Efficacy of Sonocloud Device Combined With Nivolumab in Brain Metastases From Patients With Melanoma (Phase 1|Phase 2) NCT04021420
628. A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 NSCLC That is Unable or Not Planned to be Removed by Surgery (Phase 3) NCT04026412
629. ImmunoPET With an Anti-CD8 Imaging Agent (Phase 1|Phase 2) NCT04029181
630. Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (Phase 2) NCT04034927
631. A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma (Phase 3) NCT04039607
632. Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors (Phase 2) NCT04042753
633. Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC (Phase 1|Phase 2) NCT04043195
634. A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan () NCT04043975
635. CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI) (Phase 1|Phase 2) NCT04060407
636. Perioperative Chemotherapy vs Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (Phase 2) NCT04062656
637. Study of ARRY-614 Plus Either Nivolumab or Ipilimumab (Phase 1|Phase 2) NCT04074967
638. Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (Phase 2) NCT04079712
639. Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (Phase 2) NCT04080804
640. A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma (Phase 2) NCT04088500
641. SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer (Phase 2) NCT04090710
642. A Phase 2 Trial for Men With Metastatic Prostatic Adenocarcinoma (Phase 2) NCT04090775
643. Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma (Phase 2) NCT04091750
644. Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintalolimid, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (Phase 2) NCT04093323
645. Microbiome Immunotherapy Toxicity and Response Evaluation () NCT04107168
646. Phase IB/II Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer (Phase 1|Phase 2) NCT04109729
647. Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected MMR-p Colorectal and Pancreatic Cancer (Phase 1) NCT04117087
648. Ipilimumab +Nivolumab + Cryotherapy in Metastatic or Locally Advanced Soft Tissue Sarcoma (Phase 2) NCT04118166
649. Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer (Phase 2) NCT04124601
650. Nivolumab/Ipilimumab in Second Line CUP-syndrome (Phase 2) NCT04131621
651. A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2-Breast Cancer That Has Spread (Phase 1) NCT04132817
652. Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma (Phase 1|Phase 2) NCT04133948
653. Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment. (Phase 2) NCT04134182
654. BioForte Technology for in Silico Identification of Candidates for a New Microbiome-based Therapeutics and Diagnostics () NCT04136470
655. PhIb Study Evaluating Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC (Phase 1) NCT04141644
656. A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) for People With Recurrent Glioblastoma With Elevated Mutational Burden (Phase 2) NCT04145115
657. AImmune – Artificial Intelligence Algorithm for Identification of Immunogenic Neoepitopes of Cancer to Predict and Boost Patient’s Response to Immunotherapies. () NCT04145232
658. Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response () NCT04146064
659. CaboCHECK – Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study () NCT04147143

2019年度ノーベル化学賞受賞者の発表

 吉野彰氏の記者会見

ノーベル化学賞の旭化成・吉野彰氏「リチウムイオン電池が受賞してうれしい」（2019年10月9日 THE PAGE ザ・ページ）

吉野彰氏の略歴：
1966年 – 大阪府立北野高等学校卒業
1970年 – 京都大学工学部石油化学科卒業
1972年 – 京都大学大学院工学研究科石油化学専攻修士課程修了
1972年 – 旭化成工業株式会社（現旭化成株式会社）入社
（参照：ウィキペディア）

リチウムイオン電池の誕生

2018 Japan Prize Commemorative Lecture: Dr. Akira Yoshino 　2018/04/23 　JapanPrize